News

April 18, 2012
čára

PrimeCell to participate at the World Stem Cells Congress

PrimeCell is pleased to announce its participation at The 2012 World Stem Cells and Regenerative Medicine Congress, the region´s largest conference within the industry, which is scheduled to take place on May 21 – 23, 2012 in London, UK, at Victoria Park Plaza.

read more >>

April 4, 2012
čára

PrimeCell extends its technology portfolio

PrimeCell, emerging regenerative medicine firm in the Czech Republic, is pleased to announce that TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications is installing a system, namely, CellBase CT™ to improve reproducibility and affordability of its autologous cell therapies.

read more >>

February 20, 2012
čára

German research companies set sights on the Czech Republic

According to Germany Trade and Invest the Czech Republic is increasingly becoming and an attractive market within the research and development industry, which enhances investment opportunities for German companies.

read more >>

September 21, 2011
čára

NTC in the Millennium show

Mr. Michal Zahradníček, the chair of the NTC supervisory board, was a guest of Monday’s Millenium TV magazine.

read more >>

September 15, 2011
čára

NTC under the auspices of Brno

The city of Brno, represented by its chief magistrate Roman Onderka, has taken over the sponsorship for the National Tissue Center projects. The projects are mostly related to the research of new types of materials and experimental development of modern therapy devices.

September 13, 2011
čára

Grand opening

The grand opening of the National Tissue Center in Brno Bohunice is scheduled for 15th September 2011. Guests will have the option of examining the super-clean areas of the NTC production laboratories. The Minister of Health of the Czech Republic, doc. MUDr. Leoš Heger, CSc., will also be present at the grand opening.

September 10, 2011
čára

The United States government won a Federal Court lawsuit in the battle for stem cells

Obama’s government won a lawsuit at the Federal Court on 27th June 2011 regarding the temporary suspension of embryonic stem cell research. The federal judge has rejected the action proposed by two scientists who were trying to stop the financing of research on human embryos by the federal government. The decision is a victory for the advocates of controlled and government-financed modern research of human diseases. The area of embryonic stem cell research is highly controversial, as in most cases the embryo dies within 4-5 days after stem cells are withdrawn.

read more >>

August 29, 2011
čára

Press conference for the introduction of the National Tissue Center, a.s. (NTC)

The press conference took place on Thursday 25th August in Prague. MUDr. Roman Kraus, the director of University Hospital Brno, MUDr. Barbara Kubešová, the head physician and director of NTC, Prof. MUDr. Pavel Brychta, CSc., the head of the Burn and Reconstruction Surgery Clinic at University Hospital Brno, MUDr. Pavel Březovský, MBA, director of the Transplantation Coordination Center for the Czech Republic and RNDr. Eva Matějková, the head of the Cellular Therapy Department and qualified specialist for the production of medications at NTC, have introduced the newly constructed research, development and production facilities of the National Tissue Center. The new modern laboratories at NTC comply with all strict legislative requirements and all the criteria on the level of cleanness, and will host the development and production of preparations used in modern therapy, cellular therapy and of tissue transplants.

read more >>

August 15, 2011
čára

Chondros s.r.o. receive a trademark

Our subsidiary Chondros s.r.o. has received a trademark. The registration of the trademark is a continuation of the company's unique business strategy. The trademark registration is available for download here.

August 4, 2011
čára

First medication from stem cells approved for clinical use in South Korea

After six years of extensive clinical studies, the South Korean Food and Drug Administration has approved stem cells for clinical use. South Korea is the first country in the world to allow treatment of patients by stem cells.  Development biotechnology companies have developed and clinically tested a medication obtained via cultivation from stem cells of the bone marrow. The preparation is designated for treating patients with acute coronary syndrome, and is applied intravenously to patients after an acute cardiac event. The producer claims that a single injection improves heart operation by 6% within six months. Further clinical studies and efficiency testing are planned.

July 15, 2011
čára

Transplantology helps new life

We can expect further developments in transplantology following the recent successful facial transplant realized by Czech doctor MUDr. Bohdan Pomahač in the United States and many other extraordinary surgical operations in the Czech Republic and abroad. Transplants can be used, based on the type of wound or disease, to save lives, improve quality of living or significantly extend one's life. It can also be a very important tool in helping the creation of new life, as we have just found out.

A woman with a transplanted heart has given birth last week to a healthy girl in the maternity hospital U Apolináře. This is the first such event in the Czech Republic. The news was given by the head of the cardiocenter of Prague’s Institute for Clinical and Experimental Medicine, prof. Jan Pirk, who performed the transplant 2.5 years ago.

July 11, 2011
čára

Amendment of health insurance law presents a new opportunity for the treatment of patients with medical preparations of the National Tissue Center

On 21st June 2011 the Chamber of Deputies of the Czech Republic has approved a novelization of the law on public health insurance no. 48/1997.

read more >>

 

PrimeCell Therapeutics a.s. je biotechnologická společnost vyvíjející léčivé přípravky z lidských buněk s cílem zlepšit kvalitu lidského života. Využíváme přirozené léčivé a regenerativní vlastnosti buněk. Speciálními manipulacemi ovlivňujeme vlastnosti buněk tak, aby léčebného účinku bylo dosaženo v postižených tkáních.

 

 

Využíváme přirozených léčivých a regenerativních vlastností buněk a jejich součástí. Speciálními ověřenými postupy ovlivňujeme vlastnosti buněk tak, abychom dosáhli léčebného účinku v postižených tkáních.

PrimeCell Therapeutics a.s. poskytuje pacientům nové metody vysoce personalizované efektivní léčby, které využívají lidské buňky a tkáně a to především v případech, kdy stav pacientů nelze léčit běžnými léčivy nebo jinou konvenční metodou, či je-li léčba lidskými buňkami pro pacienta šetrnější. Bude se věnovat především přípravě autologních a alogenních léčivých přípravků pro ortopedické indikace, ischemické choroby, kožní defekty nebo hojení ran.

 

Jedním ze základů aktivit PrimeCell Therapeutics a.s je intenzivní spolupráce s renomovanými tuzemskými a světovými vědeckými institucemi a klinickými centry s cílem využít výsledky základního výzkumu v klinické praxi, a to co nejrychleji ku prospěchu pacientů. Dále bude rozvíjena dosavadní síť více než sto klinických center a partnerů v České republice a v zahraničí.

 

PrimeCell Therapeutics a.s. byl založen v roce 2007. Je jedním z nejvýznamnějších investorů v Evropě v oblasti regenerativní medicíny. Vlastní a provozuje vysoce moderní vývojovou a výrobní infrastrukturu pro aplikovaný vývoj, zpracování a výrobu lidských buněk a tkání. Ve svém portfoliu má téměř 8000 m2 laboratorních prostor, z toho 2000 m2 cGMP zázemí pro vývoj a výrobu buněčných a tkáňových produktů. Více o infrastruktuře PrimeCell Therapeutics a.s. naleznete na www.natic.cz a www.4medi.cz

 

  About us
who we are
corporate Overview executive
and non-executive

directors
our history
partnerships and our
responsibility
Advanced & Cell Therapy

Key programs & products
current products
products in the pipeline
stories
Research
our innovative strategy
research areas
our developments
co-operation opportunites
Media
news
PrimeCell in media
odborné publikace
photogallery
corporate identity
About 4MEDi

Contact us
contact us
informace pro akcionáře
PrimeCell Therapeutics a.s.
Sídlo: Jáchymova 26/2 Praha 1/ 110 00
Office: U Plynárny 1002/97 Praha 10/ 101 00

Praha / Brno / Ostrava / New York / Singapore / Jeddah
© by primecell | pupečníková krev | design by upsala